Engineering Protein Nanoparticles for Enhanced Vaccine Delivery

Brief Description

A revolutionary vaccine platform enabling the co-delivery of multiple toll-like receptor agonists and an antigen for potent immune responses.

Full Description

This technology utilizes engineered protein nanoparticles (NPs) to co-deliver toll-like receptor (TLR) agonists and a protein antigen, aiming to elicit stronger, broader, and more efficacious immune responses. This approach allows for stable vaccines that can simultaneously deliver active components in a consistent and uniform molecular orientation, enhancing the immunogenicity of vaccines against infectious diseases. As a result, this platform overcomes the limitations of conventional subunit vaccines, such as rapid draining kinetics and reduced immunostimulatory capacity.

Suggested uses

• Development of next-generation vaccines for infectious diseases. 
• Prophylactic vaccines offering broader protection against emerging pandemic pathogens. 
• Modular vaccine platforms for rapid response to seasonal and pandemic influenza strains.

Advantages

• Simultaneous delivery of multiple adjuvants and an antigen on a single nanoparticle. 
• Enhanced immunogenicity through consistent and uniform molecular orientation of components. 
• Improves the strength, breadth, and bias of immune responses against infectious diseases. 
• Offers a modular approach, allowing for the customization of vaccine formulations to target different pathogens. 
• Potentially reduces the need for annual vaccine reformulations and improves protection against emerging pathogens.

Patent Status

Patent Pending

Related Materials

• Ramirez, A., et al. Davies, D. H., Wang, S.-W. (2023). Engineering Protein Nanoparticles Functionalized with an Immunodominant Coxiella burnetii Antigen to Generate a Q Fever Vaccine. Bioconjugate Chem. 34 (9).
• Badten, A. J., Ramirez, A., et al. Davies, D. H., Wang, S.-W. (2023). Protein Nanoparticle-Mediated Delivery of Recombinant Influenza Hemagglutinin Enhances Immunogenicity and Breadth of the Antibody Response. ACS. Infect. Dis. 9 (2).